Skip to content
Licensed Unlicensed Requires Authentication Published by De Gruyter May 5, 2018

Update in diagnosis and management of primary aldosteronism: reply to a Letter to the Editor

Sofia Michele Dick, Marina Queiroz, Letícia Almeida Brondani, Angélica Dall’Agnol, Bárbara Luisa Bernardi and Sandra Pinho Silveiro

  1. Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.

  2. Research funding: None declared.

  3. Employment or leadership: None declared.

  4. Honorarium: None declared.

  5. Competing interests: The funding organization(s) played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.


1. Gay A. Letter to the Editor relative to Clin Chem Lab Med 2018;56(3):360–372. Clin Chem Lab Med 2018;56:e251–2.10.1515/cclm-2018-0245Search in Google Scholar

2. Dick SM, Queiroz M, Bernardi BL, Dall’Agnol A, Brondani LA, Silveiro SP. Update in diagnosis and management of primary aldosteronism. Clin Chem Lab Med 2018;56:360–72.10.1515/cclm-2017-0217Search in Google Scholar

3. Gromotowicz-Poplawska A, Szoka P, Kolodziejczyk P, Kramkowski K, Wojewodzka-Zelezniakowicz M, Chabielska E. New agents modulating the renin-angiotensin-aldosterone system – will there be a new therapeutic option? Exp Biol Med (Maywood) 2016;241:1888–99.10.1177/1535370216660211Search in Google Scholar

4. Pitt B, Kober L, Ponikowski P, Gheorghiade M, Filippatos G, Krum H, et al. Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, doubleblind trial. Eur Heart J 2013;34:2453–63.10.1093/eurheartj/eht187Search in Google Scholar

5. Filippatos G, Anker SD, Böhm M, Gheorghiade M, Køber L, Krum H, et al. A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease. Eur Heart J 2016;37:2105–14.10.1093/eurheartj/ehw132Search in Google Scholar

6. Bärfacker L, Kuhl A, Hillisch A, Grosser R, Figueroa-Perez S, Heckroth H, et al. Discovery of BAY 94-8862: a nonsteroidal antagonist of the mineralocorticoid receptor for the treatment of cardiorenal diseases. Chem Med Chem 2012;7:1385–403.10.1002/cmdc.201200081Search in Google Scholar

7. Bramlage P, Swift SL, Thoenes M, Minguet J, Ferrero C, Schmieder RE. Non-steroidal mineralocorticoid receptor antagonism for the treatment of cardiovascular and renal disease. Eur J Heart Fail 2016;18:28–37.10.1002/ejhf.444Search in Google Scholar

8. Kolkhof P, Delbeck M, Kretschmer A, Steinke W, Hartmann E, Bärfacker L, et al. Finerenone, a novel selective nonsteroidal mineralocorticoid receptor antagonist protects from rat cardiorenal injury. J Cardiovasc Pharmacol 2014;64:69–78.10.1097/FJC.0000000000000091Search in Google Scholar

Received: 2018-03-26
Accepted: 2018-03-29
Published Online: 2018-05-05
Published in Print: 2018-10-25

©2018 Walter de Gruyter GmbH, Berlin/Boston

Scroll Up Arrow